Pell Bio-Med Technology Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	29.99	19.63	18.03	17.16	13.98
Revenue Growth (YoY)	62.90%	8.86%	5.11%	22.75%	-
Cost of Revenue	39.33	31.96	44.17	28.41	18.35
Gross Profit	-9.33	-12.33	-26.14	-11.26	-4.37
Selling, General & Admin	142.67	135.01	145.49	82.24	54.78
Research & Development	248.16	266.16	239.61	142.55	136.82
Operating Expenses	390.82	401.17	385.11	224.85	191.59
Operating Income	-400.15	-413.5	-411.25	-236.11	-195.96
Interest Expense	-4.93	-2.26	-2.56	-1.36	-1.52
Interest & Investment Income	11.4	15.37	7.63	2.27	0.24
Earnings From Equity Investments	-0.03	0.11	0.11	-0	0.01
Currency Exchange Gain (Loss)	-1.46	0.1	0.09	1.52	-0.51
Other Non Operating Income (Expenses)	1.49	5.82	4.86	2.41	8.97
EBT Excluding Unusual Items	-393.69	-394.36	-401.11	-231.27	-188.76
Gain (Loss) on Sale of Investments	4.61	-0.62	-	-	-
Gain (Loss) on Sale of Assets	-	-0.14	-0.13	-	-0.2
Pretax Income	-389.08	-395.12	-401.24	-231.27	-188.96
Income Tax Expense	-	-	0	-	-
Earnings From Continuing Operations	-389.08	-395.12	-401.24	-231.27	-188.96
Minority Interest in Earnings	15.37	5.7	2.48	1.14	-
Net Income	-373.72	-389.42	-398.76	-230.13	-188.96
Net Income to Common	-373.72	-389.42	-398.76	-230.13	-188.96
Shares Outstanding (Basic)	59	57	46	39	33
Shares Outstanding (Diluted)	59	57	46	39	33
Shares Change (YoY)	6.22%	23.33%	17.94%	17.87%	-
EPS (Basic)	-6.38	-6.83	-8.62	-5.87	-5.68
EPS (Diluted)	-6.39	-6.83	-8.62	-5.87	-5.68
Free Cash Flow	-571.76	-523.91	-196.48	-167.48	-122.32
Free Cash Flow Per Share	-9.76	-9.18	-4.25	-4.27	-3.68
Gross Margin	-31.12%	-62.79%	-144.96%	-65.61%	-31.27%
Operating Margin	-1334.16%	-2106.35%	-2280.52%	-1376.17%	-1402.03%
Profit Margin	-1246.01%	-1983.67%	-2211.26%	-1341.32%	-1351.93%
Free Cash Flow Margin	-1906.30%	-2668.77%	-1089.53%	-976.14%	-875.12%
EBITDA	-381.01	-394.04	-392.04	-217.36	-178.32
D&A For EBITDA	19.14	19.46	19.21	18.75	17.65
EBIT	-400.15	-413.5	-411.25	-236.11	-195.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.